Simeprevir receives positive CHMP opinion for the treatment of adults with chronic hepatitis C in the European Union

  · Positive opinion for the use of simeprevir in combination with other
medicinal products for the treatment of chronic hepatitis C (CHC) in adult
patients.

Stockholm, Sweden — Medivir AB (OMX: MVIR) announced today that the Committee
for Medicinal Products for Human Use (CHMP) has adopted a positive opinion,
recommending Marketing Authorisation in the European Union for the use of
simeprevir in combination with other medicinal products for the treatment of
chronic hepatitis C (CHC) in adult patients.

“The recommendation is one additional step in the global strategy that our
partner Janssen has for simeprevir, to offer a new and efficacious treatment
option to the many hepatitis C patient groups suffering from this devastating
disease” said Maris Hartmanis CEO, Medivir.

Simeprevir is a new generation, NS3/4A protease inhibitor administered as a once
daily 150 mg capsule with pegylated interferon (PegIFN) and ribavirin (RBV)
offering proven efficacy across a range of different HCV patient types.

The CHMP opinion was based on positive and consistent results from three pivotal
phase III studies in patients with GT1 HCV; QUEST-1 and QUEST-2 in treatment
-naïve patients and PROMISE in patients (who have relapsed after previous
interferon-based therapy). QUEST-1 and QUEST-2 included 785 treatment-naïve
patients with chronic HCV GT1 infection. PROMISE included 393 relapsed patients
with chronic HCV GT1 infection. All three studies met their primary end points
and demonstrated simeprevir in combination with PegIFN/RBV achieves superior
cure rates when compared with PegIFN/RBV alone, in treatment naïve and relapsed
patients.

Hepatitis C in the European Union
Hepatitis C is a major health problem in the European Union, where nine million
people are living with the disease. The current standard of care is not always
tolerable due to significant side effects of interferon based therapy and
improvements in efficacy for difficult to treat patients, such as prior null
responders, represent a high medical need. Treatment of HCV is complex because
of the heterogeneous population of patients it affects and that treatment
efficacy is highly dependent on the genotype of the virus.

For more information please contact:
Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292

Medivir is required under the Securities Markets Act to make the information in
this press release public. The information was submitted for publication at
15.45 CET on 21 March 2014.


About Simeprevir
Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D
Ireland and Medivir AB and indicated for the treatment chronic hepatitis C
infection in combination with pegylated interferon and ribavirin in HCV genotype
1 and 4 infected patients with compensated liver disease, including cirrhosis.

Janssen is responsible for the global clinical development of simeprevir and has
exclusive, worldwide marketing rights, except in the Nordic countries. Medivir
AB will retain marketing rights for simeprevir in these countries under the
marketing authorization held by Janssen-Cilag International NV. Simeprevir was
approved for the treatment of genotype 1 hepatitis C in September 2013 in Japan
and in November 2013 in Canada and the U.S.

About Medivir
Medivir is an emerging research-based pharmaceutical company focused on
infectious diseases. Medivir has world class expertise in polymerase and
protease drug targets and drug development which has resulted in a strong
infectious disease R&D portfolio. The Company’s key pipeline asset is
simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is
being developed in collaboration with Janssen R&D Ireland. The company is also
working with research and development in other areas, such as bone disorders and
neuropathic pain. Medivir has also a broad product portfolio with prescription
pharmaceuticals in the Nordics.

For more information about Medivir AB, please visit the Company’s website:
www.medivir.com